{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:57:48Z","timestamp":1787029068175,"version":"build-2736575974"},"reference-count":49,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Lianyungang Hi-tech Industrial Development Zone","award":["ZD201916"],"award-info":[{"award-number":["ZD201916"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Olanzapine is a commonly used drug in the treatment of schizophrenia, but its clinical application has been restricted by metabolic-related side effects. In order to mitigate the weight gain side effects caused by olanzapine, other drugs with different targets were selected for combined use and evaluated in animal models of schizophrenia. SEP-363856 is a novel psychotropic agent which is under phase III clinical trials for schizophrenia treatment. The aim of the research was to evaluate whether co-administration of olanzapine and SEP-363856 exerts synergistic anti-schizophrenic effects in the apomorphine (APO)-induced climbing test, the MK-801-induced hyperactivity test, and the Morris water maze test, and therefore reduces the weight gain side effects induced by olanzapine. Through isobolographic analysis, the results showed a synergistic interaction in the climbing test; the experimental ED30 (3 mg\/kg) was significantly smaller (p &lt; 0.05) than the theoretical ED30 (5 mg\/kg). Additionally, such potentiating effects appeared additive in the MK-801 challenge experiment. Co-treatment with an effective dose of olanzapine and a low dose of SEP-363856 reversed MK-801-induced cognitive impairment symptoms in mice. Moreover, combination treatment with olanzapine and SEP-363856 controls sustained weight gain in mice with chronic exposure to olanzapine. These results support further clinical trials to test the effectiveness of co-treatment of olanzapine and SEP-363856 for controlling symptoms and weight gain in patients with schizophrenia during antipsychotic treatments.<\/jats:p>","DOI":"10.3390\/molecules27082550","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T01:03:01Z","timestamp":1650330181000},"page":"2550","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia"],"prefix":"10.3390","volume":"27","author":[{"given":"Lingzhi","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlin","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China"},{"name":"Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature09552","article-title":"Rethinking schizophrenia","volume":"468","author":"Insel","year":"2010","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.biopsych.2017.11.008","article-title":"The Mediodorsal Thalamus: An Essential Partner of the Prefrontal Cortex for Cognition","volume":"83","author":"Parnaudeau","year":"2018","journal-title":"Biol. Psychiatry."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1021\/acs.jmedchem.8b01096","article-title":"Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives as Potential Multireceptor Atypical Antipsychotics","volume":"61","author":"Cao","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/0964704X.2012.664087","article-title":"The chlorpromazine enigma","volume":"22","author":"Baumeister","year":"2013","journal-title":"J. Hist. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: A review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/JCP.0000000000001205","article-title":"Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia","volume":"40","author":"Meltzer","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S2215-0366(20)30341-2","article-title":"Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): A pragmatic, rater-blind, semi-randomised trial","volume":"7","author":"Johnsen","year":"2020","journal-title":"Lancet Psychiat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/0269881118756061","article-title":"Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats","volume":"32","author":"Babic","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/00023210-200115110-00005","article-title":"Olanzapine: A review of its use in the treatment of bipolar I disorder","volume":"15","author":"Bhana","year":"2001","journal-title":"CNS Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"Mcevoy","year":"2006","journal-title":"Am. J. Psychiat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.lfs.2007.01.038","article-title":"Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine","volume":"80","author":"Uchida","year":"2007","journal-title":"Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1172\/JCI93362","article-title":"The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C","volume":"127","author":"Lord","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D(2) Receptor Mechanism of Action","volume":"371","author":"Dedic","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Begni, V., Sanson, A., Luoni, A., Sensini, F., Grayson, B., Munni, S., Neill, J.C., and Riva, M.A. (2021). Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084119"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbrc.2019.02.152","article-title":"The gut microbiota promotes the pathogenesis of schizophrenia via multiple pathways","volume":"512","author":"Yuan","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20081","DOI":"10.1073\/pnas.0906522106","article-title":"The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system","volume":"106","author":"Bradaia","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(06)78001-1","article-title":"Neurobiology of dopamine in schizophrenia","volume":"78","author":"Guillin","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight","volume":"18","author":"Revel","year":"2013","journal-title":"Mol. Psychiatr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/070674370404900213","article-title":"Aripirazole-olanzapine combination for treatment of schizophrenia","volume":"49","author":"Duggal","year":"2004","journal-title":"Can. J. Psychiat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/13696998.2019.1580714","article-title":"Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China","volume":"22","author":"Zhao","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_24","first-page":"5289","article-title":"The pharmacological properties and therapeutic use of apomorphine","volume":"5","year":"2012","journal-title":"Molecules"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/sj.npp.1300460","article-title":"Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents","volume":"29","author":"Ugale","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.phymed.2014.06.015","article-title":"Synergistic effect of the interaction between curcumin and diclofenac on the formalin test in rats","volume":"21","author":"Ortiz","year":"2014","journal-title":"Phytomedicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-010-1938-0","article-title":"Validation and pharmacological characterization of MK-801-induced locomotor hyperactivity in BALB\/C mice as an assay for detection of novel antipsychotics","volume":"212","author":"Bradford","year":"2010","journal-title":"Psychopharmacology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1515\/jbcpp-2015-0045","article-title":"Histamine H3 receptor antagonists display antischizophrenic activities in rats treated with MK-801","volume":"27","author":"Mahmood","year":"2016","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.pbb.2010.07.016","article-title":"Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential","volume":"97","author":"Alberati","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00210-018-1500-x","article-title":"Effects of the monoamine stabilizer (-)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity","volume":"391","author":"Matosinhos","year":"2018","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1478-811X-8-12","article-title":"Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis","volume":"8","author":"Wolf","year":"2010","journal-title":"Cell Commun. Signal."},{"key":"ref_32","first-page":"897","article-title":"Morris Water Maze Experiment","volume":"19","author":"Nunez","year":"2008","journal-title":"J. Vis. Exp."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1017\/S1461145714000509","article-title":"TAAR1-dependent effects of apomorphine in mice","volume":"17","author":"Sukhanov","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ygeno.2004.11.010","article-title":"Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors","volume":"85","author":"Lindemann","year":"2005","journal-title":"Genomics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/jpet.105.084459","article-title":"Primate trace amine receptor 1 modulation by the dopamine transporter","volume":"3","author":"Miller","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nagai, Y., Takayama, K., Nishitani, N., Andoh, C., Koda, M., Shirakawa, H., Nakagawa, T., Nagayasu, K., Yamanaka, A., and Kaneko, S. (2020). The Role of Dorsal Raphe Serotonin Neurons in the Balance between Reward and Aversion. Int. J. Mol. Sci., 6.","DOI":"10.3390\/ijms21062160"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neubiorev.2020.09.028","article-title":"Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?","volume":"120","author":"Dodd","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of Olanzapine Combined with Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study","volume":"177","author":"Correll","year":"2020","journal-title":"Am. J. Psychiatr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0166-2236(00)01886-5","article-title":"Genetic animal models: Focus on schizophrenia","volume":"24","author":"Gainetdinov","year":"2001","journal-title":"Trends Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.biopsych.2017.09.022","article-title":"Prefrontal-Thalamic Anatomical Connectivity and Executive Cognitive Function in Schizophrenia","volume":"83","author":"Rogers","year":"2018","journal-title":"Biol. Psychiat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.biopsych.2010.06.023","article-title":"Psychostimulants as cognitive enhancers: The prefrontal cortex, catecholamines, and attention-deficit\/hyperactivity disorder","volume":"69","author":"Berridge","year":"2011","journal-title":"Biol. Psychiat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.9758\/cpn.2016.14.3.279","article-title":"Differential Effects of Olanzapine and Haloperidol on MK-801-induced Memory Impairment in Mice","volume":"14","author":"Song","year":"2016","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/1073858403252674","article-title":"Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia","volume":"9","author":"Moore","year":"2003","journal-title":"Neuroscientist"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e20202484","DOI":"10.1084\/jem.20202484","article-title":"The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain","volume":"218","author":"Li","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10571-019-00772-7","article-title":"Actions of Trace Amines in the Brain-Gut-Microbiome Axis via Trace Amine-Associated Receptor-1 (TAAR1)","volume":"40","author":"Olliffe","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Guerrero-Solano, J.A., Bautista, M., Vel\u00e1zquez-Gonz\u00e1lez, C., De la O-Arciniega, M., Gonz\u00e1lez-Olivares, L.G., Fern\u00e1ndez-Moya, M., and Jaramillo-Morales, O.A. (2021). Antinociceptive Synergism of Pomegranate Peel Extract and Acetylsalicylic Acid in an Animal Pain Model. Molecules, 26.","DOI":"10.3390\/molecules26185434"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.phymed.2013.07.006","article-title":"Synergistic interactions between the antinociceptive effect of Rhodiola rosea extract and B vitamins in the mouse formalin test","volume":"20","year":"2013","journal-title":"Phytomedicine"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/8\/2550\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:54:29Z","timestamp":1760136869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/8\/2550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["molecules27082550"],"URL":"https:\/\/doi.org\/10.3390\/molecules27082550","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}